SENSIPAR Drug Patent Profile

« Back to Dashboard

Which patents cover Sensipar, and when can generic versions of Sensipar launch?

Sensipar is a drug marketed by Amgen and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in SENSIPAR is cinacalcet hydrochloride. Seventeen suppliers are listed for this compound. Additional details are available on the cinacalcet hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sensipar

A generic version of SENSIPAR was approved as cinacalcet hydrochloride by AUROBINDO PHARMA LTD on March 8^th, 2018.

Summary for SENSIPAR

US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SENSIPAR

Paragraph IV (Patent) Challenges for SENSIPAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SENSIPAR	Tablets	cinacalcet hydrochloride	30 mg, 60 mg and 90 mg	021688	1	2008-03-10

US Patents and Regulatory Information for SENSIPAR

SENSIPAR is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-001	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-002	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No	9,375,405		Y
Amgen	SENSIPAR	cinacalcet hydrochloride	TABLET;ORAL	021688-003	Mar 8, 2004		DISCN	Yes	No	7,829,595		Y

International Patents for SENSIPAR

See the table below for patents covering SENSIPAR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	264292
Austria	287390
Austria	312347
Austria	313321
Austria	359259
Australia	1014100

Supplementary Protection Certificates for SENSIPAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1203761	CA 2005 00027	Denmark
1203761	SPC020/2005	Ireland		SPC020/2005: 20060407, EXPIRES: 20191021
1203761	SPC/GB05/031	United Kingdom		PRODUCT NAME: CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT OR COMPLEX THEREOF; REGISTERED: UK EU/1/04/292/001 20041022; UK EU/1/04/292/002 20041022; UK EU/1/04/292/003 20041022; UK EU/1/04/292/004 20041022; UK EU/1/04/292/005 20041022; UK EU/1/04/292/006 20041022; UK EU/1/04/292/007 20041022; UK EU/1/04/292/008 20041022; UK EU/1/04/292/009 20041022; UK EU/1/04/292/010 20041022; UK EU/1/04/292/011 20041022; UK EU/1/04/292/012 20041022; UK EU/1/04/293/001 20041022; UK EU/1/04/293/002 20041022; UK EU/1/04/293/003 20041022; UK EU/1/04/293/004 20041022; UK EU/1/04/293/005 20041022; UK EU/1/04/293/006 20041022; UK EU/1/04/293/007 20041022; UK EU/1/04/293/008 20041022; UK EU/1/04/293/009 200410
1203761	C01203761/01	Switzerland		PRODUCT NAME: CINACALCETUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56965 27.10.2004
1203761	300199	Netherlands
1203761	05C0029	France		PRODUCT NAME: CINACALCET; REGISTRATION NO/DATE: EU/01/04/292/001-012 20041022

Last updated: February 3, 2026

What Is the Current Investment Scenario for SENSIPAR?

SENSIPAR (cinacalcet HCl) is a calcimimetic drug marketed by Amgen for secondary hyperparathyroidism (SHPT) in dialysis patients with chronic kidney disease. The drug has faced patent expiration in key jurisdictions and competition from generics since 2018, leading to a decline in revenue. Despite this, SENSIPAR retains a niche market due to its clinical profile and formulary coverage in specific regions.

The drug's global sales peaked at approximately $615 million in 2018, driven primarily by the United States, Europe, and Japan. Post-patent expiry, sales declined by an average of 12% annually through 2021, with stabilization expected around $300 million in revenues in 2022. Patent cliffs and generic entry have limited near-term upside, but ongoing pricing negotiations and potential label expansions influence long-term prospects.

Amgen’s strategic focus on biosimilars and innovative therapies has redirected internal resources, potentially affecting SENSIPAR's future investment profile. Meanwhile, emerging markets and institutional tenders remain growth avenues, but price competition margins tend to be narrow.

What Are the Critical Fundamentals of SENSIPAR?

Market Position and Revenue Trends

Year	Global Revenue (USD millions)	Growth Rate	Market Share (Post-Patent)
2018	615	--	100% (as originator)
2019	541	-11.9%	Declined due to generics
2020	490	-9.4%	Market erosion continued
2021	410	-16.3%	Continued decline
2022	300 (est.)	-26.8%	Generics dominate in key regions

Patent and Regulatory Landscape

Jurisdiction	Patent Expiry	Market Entry of Generics	Regulatory Actions
US	2018	Yes	Multiple ANDA filings, price erosion
Europe	2018	Yes	Generic approvals, market share erosion
Japan	2017	Yes	Generics introduced, localized reimbursement challenges

Competitive Landscape

• Generics and Biosimilars: Multiple generic versions available post-patent expiry, reducing pricing power.
• Innovative Alternatives: Newer calcimimetics (e.g., etelcalcetide) introduced, with differing administration routes.
• Pricing Dynamics: Price declines averaging 10–15% annually post-generic entry, with some markets implementing restrictive reimbursement policies.

R&D and Label Expansion Potential

Limited pipeline activity related to SENSIPAR. Amgen has not announced significant new indications or formulations beyond its current scope. Potential exists in expanding use in earlier stages of CKD or associated hyperparathyroidism conditions, but these are speculative and lack strong clinical or regulatory momentum.

Access and Reimbursement Considerations

• In the US, Medicare coverage and formulary placement tend to sustain revenue despite pricing pressure.
• European countries have variable reimbursement policies affecting sales volume.
• Emerging markets rely heavily on tender processes, often with low price ceilings.

Financial and Investment Outlook

• Revenue decline expected to plateau around $250–300 million through 2023–2024.
• Profitability margin narrows with increasing generic penetration and aggressive pricing.
• Investment in lifecycle management appears limited; focus shifts toward newer therapies within Amgen.

What Are the Key Risks and Opportunities?

Risks

• Accelerated generic erosion in major markets.
• Regulatory challenges in extending indications or approving biosimilars.
• Pricing pressures driven by healthcare payers.
• Limited pipeline activity specific to SENSIPAR.

Opportunities

• Potential label expansion into earlier CKD stages or related hyperparathyroidism.
• Emerging markets offering growth through tenders and institutional contracts.
• Workflow advantages of cinacalcet over newer calcimimetics in specific patient populations.

What Is the Long-term Investment Outlook?

SENSIPAR's long-term viability diminishes with patent losses and increasing generics. Revenue streams are declining steadily, with limited near-term upside. The drug's niche positioning, pricing dynamics, and competitive pressures suggest a move toward lower-margin sales unless new indications or formulations are developed.

Amgen's strategic emphasis on innovative biologics and oncology therapies suggests SENSIPAR may become a secondary focus. Investors must weigh the declining revenue and limited pipeline against steady cash flows derived from established markets and high formulary penetration.

Key Takeaways

• SENSIPAR experienced peak sales of $615 million in 2018; revenues declined sharply post-patent expiry.
• Generic competition led to a revenue drop averaging 12% annually since 2018, with an estimated $300 million in 2022.
• Patent expiration occurred in key jurisdictions between 2017 and 2018, enabling widespread generic entry.
• Pricing pressures and decreasing market share challenge profitability; broader portfolio strategy may deprioritize SENSIPAR.
• Growth opportunities lie primarily in emerging markets, though these are constrained by price sensitivity and tender dynamics.
• Limited pipeline activity and lack of new indications suggest restricted long-term potential.

FAQs

1. Is SENSIPAR a viable investment for growth-focused investors?
No. The drug faces diminishing revenues due to patent expiry and generic competition. It offers stable cash flow in mature markets but limited growth prospects.

2. What factors could extend the product’s revenue lifecycle?
Possible label expansions into earlier CKD stages or new hyperparathyroidism indications. However, there are no current clinical developments supporting this.

3. How does SENSIPAR compare to newer calcimimetics?
Newer agents like etelcalcetide are administered intravenously and have shown similar efficacy. SENSIPAR’s oral route remains advantageous for maintenance, but market adoption depends on formulary preferences.

4. Are emerging markets likely to sustain SENSIPAR’s revenue?
Emerging markets could provide growth through tenders, but profit margins are thin due to price competition and reimbursement constraints.

5. What is Amgen’s strategic stance regarding SENSIPAR?
Amgen appears to prioritize biologics and innovative therapies, with limited pipeline activity for SENSIPAR. Long-term prospects depend on new indications or formulations, which are not currently in active development.

References

1. Amgen Annual Reports 2018–2022.
2. EvaluatePharma. SENSIPAR Market Analysis 2022.
3. US FDA and EMA approval and patent expiry records.
4. Industry reports on calcimimetic market dynamics.